NASDAQ:KIN - Kindred Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$12.85 +0.05 (+0.39 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$12.90
Today's Range$12.80 - $13.00
52-Week Range$6.55 - $13.00
Volume159,700 shs
Average Volume131,172 shs
Market Capitalization$352.54 million
P/E Ratio-10.45
Dividend YieldN/A
Beta0.11
Kindred Biosciences logoKindred Biosciences, Inc., a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs related to equine metabolic syndrome. It is also developing biologics programs, including KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) to treat newborn foals; and canine atopic dermatitis, an immune-mediated inflammatory, chronic skin disease related to allergies. In addition, the company engages in the development of other biologic product candidates, such as KIND-502 to treat allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a biologics scaffold technology. Further, it is developing anti-IL31, anti-IL17, and anti-IL4/13 sink antibodies for treating atopic dermatitis in dogs; anti-TNF antibody for inflammatory bowel disease in dogs; anti-IgE antibody for treating allergic diseases in dogs; anti-VEGF antibody for cancer in dogs; anti-CD20 for treating cancer and autoimmune diseases in dogs; and checkpoint inhibitors to treat cancer in dogs. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KIN
CUSIPN/A
Phone650-701-7901

Debt

Debt-to-Equity RatioN/A
Current Ratio18.56
Quick Ratio18.56

Price-To-Earnings

Trailing P/E Ratio-10.45
Forward P/E Ratio-8.40
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.00 per share
Price / Book4.28

Profitability

EPS (Most Recent Fiscal Year)($1.23)
Net Income$-30,870,000.00
Net MarginsN/A
Return on Equity-41.64%
Return on Assets-39.66%

Miscellaneous

Employees63
Outstanding Shares28,200,000
Market Cap$352.54

Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences Inc (NASDAQ:KIN) announced its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.36). View Kindred Biosciences' Earnings History.

When is Kindred Biosciences' next earnings date?

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Kindred Biosciences.

What price target have analysts set for KIN?

6 brokerages have issued twelve-month price objectives for Kindred Biosciences' shares. Their forecasts range from $11.00 to $16.75. On average, they anticipate Kindred Biosciences' share price to reach $13.25 in the next twelve months. This suggests a possible upside of 3.1% from the stock's current price. View Analyst Ratings for Kindred Biosciences.

What is the consensus analysts' recommendation for Kindred Biosciences?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Kindred Biosciences?

Kindred Biosciences saw a drop in short interest in June. As of June 29th, there was short interest totalling 278,748 shares, a drop of 54.5% from the June 15th total of 612,706 shares. Based on an average daily volume of 485,934 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.9% of the company's shares are sold short. View Kindred Biosciences' Current Options Chain.

Who are some of Kindred Biosciences' key competitors?

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the folowing people:
  • Dr. Richard Chin, Co-Founder, Pres, CEO & Director (Age 51)
  • Ms. Denise M. Bevers, Co-Founder, COO & Sec. (Age 51)
  • Ms. Wendy K. Wee, Chief Financial Officer (Age 65)
  • Dr. Hangjun Zhan, Chief Scientific Officer (Age 58)

Has Kindred Biosciences been receiving favorable news coverage?

News headlines about KIN stock have trended somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kindred Biosciences earned a news impact score of 0.11 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Kindred Biosciences' major shareholders?

Kindred Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Sit Investment Associates Inc. (0.25%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

Which major investors are buying Kindred Biosciences stock?

KIN stock was bought by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc.. View Insider Buying and Selling for Kindred Biosciences.

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $12.85.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $352.54 million. The biopharmaceutical company earns $-30,870,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Kindred Biosciences employs 63 workers across the globe.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]


MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  201 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  406
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.